Poolbeg Pharma (LON:POLB) Sets New 1-Year High – Still a Buy?

Shares of Poolbeg Pharma PLC (LON:POLB) hit a new 52-week high on Thursday . The stock traded as high as GBX 9 and last traded at GBX 8.70, with a volume of 3810007 shares traded. The stock had previously closed at GBX 8.65.

Wall Street Analyst Weigh In

Separately, Shore Capital Group reaffirmed a “house stock” rating on shares of Poolbeg Pharma in a research report on Monday, July 13th.

Poolbeg Pharma Price Performance

The company has a market cap of £66.42 million, a PE ratio of -9.26 and a beta of 1.80. The business’s 50 day moving average is GBX 7.10 and its 200-day moving average is GBX 5.47.

About Poolbeg Pharma

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity.